TY - JOUR
T1 - Does Obesity Increase Respiratory Tract Infections in Patients with Asthma?
AU - Tang, Monica
AU - Henderson, Robert J.
AU - Holbrook, Janet T.
AU - Que, Loretta G.
AU - Mathews, Anne M.
AU - Wise, Robert A.
AU - Dixon, Anne E.
AU - Peters, Stephen P.
AU - Rogers, Linda
AU - Smith, Lewis J.
AU - Teague, W. Gerald
AU - Lang, Jason E.
N1 - Funding Information:
This work was supported by the National Institutes of Health (NIH) (grant no. T32 AI007062-39 ). The associated parent studies were supported by the American Lung Association , GlaxoSmithKline (Leukotriene Modifier or Corticosteroid or Corticosteroid Salmeterol Trial, Long Acting Beta Agonist Step Down Study), and the NIH (grant nos. U01 HL080450 and U01 HL080433 for Study of Acid Reflux in Children with Asthma; U01 HL087987 , U01 HL0088367 , and U54TR001018 for Study of Soy Isoflavones in Asthma; and U01HL089464 , U01 HL089510 , UL1 TR000448 for Study of Asthma and Nasal Steroids).
Funding Information:
This work was supported by the National Institutes of Health (NIH) (grant no. T32 AI007062-39). The associated parent studies were supported by the American Lung Association, GlaxoSmithKline (Leukotriene Modifier or Corticosteroid or Corticosteroid Salmeterol Trial, Long Acting Beta Agonist Step Down Study), and the NIH (grant nos. U01 HL080450 and U01 HL080433 for Study of Acid Reflux in Children with Asthma; U01 HL087987, U01 HL0088367, and U54TR001018 for Study of Soy Isoflavones in Asthma; and U01HL089464, U01 HL089510, UL1 TR000448 for Study of Asthma and Nasal Steroids).Conflicts of interest: R. A. Wise reports grants and personal fees from AstraZeneca/Medimmune, Boehringer Ingelheim, and GSK; personal fees from Contrafect, Pulmonx, Roche, Spiration Sunovion, Merck, Circassia, Pneuma, Verona, Bonti, Denali, and Aradigm; and grants from Pearl Therapeutics, outside the submitted work; Johns Hopkins University manages conflicts of interest. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
Conflicts of interest: R. A. Wise reports grants and personal fees from AstraZeneca/Medimmune, Boehringer Ingelheim, and GSK; personal fees from Contrafect, Pulmonx, Roche, Spiration Sunovion, Merck, Circassia, Pneuma, Verona, Bonti, Denali, and Aradigm; and grants from Pearl Therapeutics , outside the submitted work; Johns Hopkins University manages conflicts of interest. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2018 American Academy of Allergy, Asthma & Immunology
PY - 2019/3
Y1 - 2019/3
N2 - Background: Because respiratory tract infections (RTIs) precede most exacerbations, a better understanding of the risk factors of RTIs and RTI-associated exacerbations in patients with asthma is a pressing public health need. Obesity in patients with asthma is associated with worse asthma control and higher asthma-associated health care utilization, but its effect on RTI risk is unknown. Objective: We aimed to study the association of body mass index (BMI) classification on the risk of self-reported RTIs and related asthma morbidity among adults and children with asthma. Methods: This post hoc analysis of 5 large asthma trials involving 747 children and 1287 adults compared BMI classification, defined as lean, overweight, and obese based on age-appropriate BMI and BMI-percentile conventions. The primary outcome was rate of visits with RTIs. Secondary asthma outcomes included upper respiratory infection (URI) severity, systemic steroid use, and health care contact. Results: Children had 1.4 times the rate of RTI compared with adults (95% confidence interval 1.27-1.56). In all participants, BMI classification did not affect the rate of visits with RTI. In children, BMI classification did not affect URI severity, all-cause asthma events, or RTI-associated asthma events. However, in adults, higher BMI classification was associated with an increase in moderate/severe URI (P =.02). Adults with higher BMI classification also had increased rates of all-cause and RTI-associated asthma exacerbations requiring systemic steroids and health care contact. Conclusions: BMI classification was not associated with an increased risk of RTIs in children or adults. In adults only, obesity was associated with increased URI severity and all-cause and RTI-associated asthma morbidity.
AB - Background: Because respiratory tract infections (RTIs) precede most exacerbations, a better understanding of the risk factors of RTIs and RTI-associated exacerbations in patients with asthma is a pressing public health need. Obesity in patients with asthma is associated with worse asthma control and higher asthma-associated health care utilization, but its effect on RTI risk is unknown. Objective: We aimed to study the association of body mass index (BMI) classification on the risk of self-reported RTIs and related asthma morbidity among adults and children with asthma. Methods: This post hoc analysis of 5 large asthma trials involving 747 children and 1287 adults compared BMI classification, defined as lean, overweight, and obese based on age-appropriate BMI and BMI-percentile conventions. The primary outcome was rate of visits with RTIs. Secondary asthma outcomes included upper respiratory infection (URI) severity, systemic steroid use, and health care contact. Results: Children had 1.4 times the rate of RTI compared with adults (95% confidence interval 1.27-1.56). In all participants, BMI classification did not affect the rate of visits with RTI. In children, BMI classification did not affect URI severity, all-cause asthma events, or RTI-associated asthma events. However, in adults, higher BMI classification was associated with an increase in moderate/severe URI (P =.02). Adults with higher BMI classification also had increased rates of all-cause and RTI-associated asthma exacerbations requiring systemic steroids and health care contact. Conclusions: BMI classification was not associated with an increased risk of RTIs in children or adults. In adults only, obesity was associated with increased URI severity and all-cause and RTI-associated asthma morbidity.
KW - Asthma
KW - Obesity
KW - Respiratory tract infections
UR - http://www.scopus.com/inward/record.url?scp=85055893554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055893554&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2018.09.033
DO - 10.1016/j.jaip.2018.09.033
M3 - Article
C2 - 30312805
AN - SCOPUS:85055893554
SN - 2213-2198
VL - 7
SP - 954-961.e6
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 3
ER -